PHAR · Pharming Group N.V.

Track PHAR — free

$9.80 +0.05 (+0.51%)

Rebalance outlook locked

Market Cap

$740.34M

70.78M

Volume · Oct 5 10.82K Avg daily vol (3M) 22.88K

Up next

Next earnings call

Nov 5, 2026 Scheduled · in 4 wks

Q2 2026 earnings call transcript

call held Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

+26.6%

Year over year

Operating margin

6.9%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+3.1%

Year over year · more shares

Price change (1Y)

-36.0%

Trailing year

Short interest

0.0%

Latest settlement · 1.2 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −33%

below

Price vs 50-day avg −13%

below

RSI (14) 34

neutral

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Very Weak

1-month return −15%

trailing

6-month return −43%

trailing

YTD return −45%

this year

Relative strength −55%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $11 › 200d $14 — 200d above 50d

Institutional flow Accumulating

+23% holders QoQ · +6 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.03% of float · ▼ -16.6% MoM · 1.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

16 holders — near 3-yr high, broad support

Squeeze score 31

low risk · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 64%

annualized · 1-yr

Max drawdown −54%

past year

ATR 4.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Jul 30, 2026

Full-year operating expense guidance · full year 2026 Initiated $315M – $320M

Full year 2026 revenue · full year 2026 Initiated $375M – $395M

Cost of goods sold as a percent of revenue · full year 2026 Initiated 11%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

4 · 2 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−33% Bearish

Price vs 50-day avg

−13% Bearish

RSI (14)

34 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $11 › 200d $14 — 200d above 50d

Institutional flow Accumulating

+23% holders QoQ · +6 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.03% of float · ▼ -16.6% MoM · 1.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

16 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $10 Now $10 · 0% Range high $21

vs 200-day avg -33% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PHAR Pharming Group N.V. this stock	$740.34M	-44.8%	—	—	0.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 0.1%
Net QoQ: +9.4K sh
Top holder: Silverberg Bernstein Capi…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

20.9K

Days to cover: 1.2d
Change: -4.2K sh

View

Short Volume

Short vol %

17%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

197

Value: $2.2K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

33.4%

Week of: Aug 31, 2026

Off-exch Lit

View

Filings

SEC Filings

Latest

6-K

Filed: Sep 29, 2026
This year: 22

View

Earnings & Events

Webcasts Upcoming

Next webcast

Nov 5, 2026

Last webcast: Sep 15, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
PHAR	-6.8%	-14.9%	-42.5%	-2.4%	-44.8%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-6.6%	-14.5%	-54.7%	-3.3%	-57.7%

Key facts CIK 1828316 CUSIP 71716E105 13F (30d) 1 filings 1 filers Visit website Investor relations

PHAR · Pharming Group N.V.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance